Aptamers and their applications in nanomedicine.

Aptamers are composed of short RNA or single-stranded DNA sequences that, when folded into their unique 3D conformation, can bind to their targets with high specificity and affinity. Although functionally similar to protein antibodies, oligonucleotide aptamers offer several advantages over protein antibodies in biomedical and clinical applications. Through the enhanced permeability and retention effect, nanomedicines can improve the therapeutic index of a treatment and reduce side effects by enhancing accumulation at the disease site. However, this targets tumors passively and, thus, may not be ideal for targeted therapy. To construct ligand-directed "active targeting" nanobased delivery systems, aptamer-equipped nanomedicines have been tested for in vitro diagnosis, in vivo imaging, targeted cancer therapy, theranostic approaches, sub-cellular molecule detection, food safety, and environmental monitoring. This review focuses on the development of aptamer-conjugated nanomedicines and their application for in vivo imaging, targeted therapy, and theranostics.

[1]  L. Gold,et al.  A tenascin-C aptamer identified by tumor cell SELEX: Systematic evolution of ligands by exponential enrichment , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[2]  C. Hong,et al.  Magnetic-assisted rapid aptamer selection (MARAS) for generating high-affinity DNA aptamer using rotating magnetic fields. , 2014, ACS combinatorial science.

[3]  H. Bermudez,et al.  Aptamer-Targeted DNA Nanostructures for Therapeutic Delivery , 2014, Molecular pharmaceutics.

[4]  Robert Langer,et al.  Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. , 2007, Nano letters.

[5]  F. Lisdat,et al.  Properties of an LNA-modified ricin RNA aptamer. , 2012, Biochemical and biophysical research communications.

[6]  R. Duncan,et al.  Nanomedicine(s) under the microscope. , 2011, Molecular pharmaceutics.

[7]  K. Greish,et al.  Nanomedicine for drug targeting: strategies beyond the enhanced permeability and retention effect , 2014, International journal of nanomedicine.

[8]  Brian A. Cohen,et al.  Targeted in vitro photodynamic therapy via aptamer-labeled, porphyrin-loaded virus capsids. , 2013, Journal of photochemistry and photobiology. B, Biology.

[9]  Sheela M. Waugh,et al.  2′-Fluoropyrimidine RNA-based Aptamers to the 165-Amino Acid Form of Vascular Endothelial Growth Factor (VEGF165) , 1998, The Journal of Biological Chemistry.

[10]  Weihong Tan,et al.  DNA aptamer–micelle as an efficient detection/delivery vehicle toward cancer cells , 2009, Proceedings of the National Academy of Sciences.

[11]  R. Langer,et al.  Drug delivery and targeting. , 1998, Nature.

[12]  Qingxin Mu,et al.  Immunomodulation of Nanoparticles in Nanomedicine Applications , 2014, BioMed research international.

[13]  Y. Jeong,et al.  Image-guided prostate cancer therapy using aptamer-functionalized thermally cross-linked superparamagnetic iron oxide nanoparticles. , 2011, Small.

[14]  L. Kèlland,et al.  Discovery and development of anticancer aptamers , 2006, Molecular Cancer Therapeutics.

[15]  Huan‐Tsung Chang,et al.  Highly efficient inhibition of human immunodeficiency virus type 1 reverse transcriptase by aptamers functionalized gold nanoparticles. , 2013, Nanoscale.

[16]  Andrew D Ellington,et al.  Construction and selection of bead-bound combinatorial oligonucleoside phosphorothioate and phosphorodithioate aptamer libraries designed for rapid PCR-based sequencing. , 2002, Nucleic acids research.

[17]  S. M. Taghdisi,et al.  Targeted delivery of Epirubicin to cancer cells by PEGylated A10 aptamer , 2013, Journal of drug targeting.

[18]  Tracy K. Pettinger,et al.  Nanopharmaceuticals (part 1): products on the market , 2014, International journal of nanomedicine.

[19]  Yong Wang,et al.  A temperature-responsive antibody-like nanostructure. , 2010, Biomacromolecules.

[20]  David D. Smith,et al.  Dual functional RNA nanoparticles containing phi29 motor pRNA and anti-gp120 aptamer for cell-type specific delivery and HIV-1 inhibition. , 2011, Methods.

[21]  Hui Chen,et al.  Molecular recognition of acute myeloid leukemia using aptamers , 2008, Leukemia.

[22]  T. Minko,et al.  Tumor targeted quantum dot-mucin 1 aptamer-doxorubicin conjugate for imaging and treatment of cancer. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[23]  Chun Xing Li,et al.  An ultra pH-sensitive and aptamer-equipped nanoscale drug-delivery system for selective killing of tumor cells. , 2013, Small.

[24]  J. Kiel,et al.  In vitro selection of DNA aptamers to anthrax spores with electrochemiluminescence detection. , 1999, Biosensors & bioelectronics.

[25]  Soonhag Kim,et al.  Bioimaging of targeting cancers using aptamer-conjugated carbon nanodots. , 2013, Chemical communications.

[26]  Omid C Farokhzad,et al.  Co‐Delivery of Hydrophobic and Hydrophilic Drugs from Nanoparticle–Aptamer Bioconjugates , 2007, ChemMedChem.

[27]  Michael Famulok,et al.  Fluorescence-activated cell sorting for aptamer SELEX with cell mixtures , 2010, Nature Protocols.

[28]  J. Katzenellenbogen,et al.  Selective Delivery of an Anticancer Drug with Aptamer-Functionalized Liposomes to Breast Cancer Cells in Vitro and in Vivo. , 2013, Journal of materials chemistry. B.

[29]  Jian Wang,et al.  Photosensitizer-gold nanorod composite for targeted multimodal therapy. , 2013, Small.

[30]  Yong Wang,et al.  A hybrid DNA aptamer-dendrimer nanomaterial for targeted cell labeling. , 2009, Macromolecular bioscience.

[31]  Chun-hua Lu,et al.  Bioresponsive controlled release using mesoporous silica nanoparticles capped with aptamer-based molecular gate. , 2011, Journal of the American Chemical Society.

[32]  Thomas Bair,et al.  Rapid Identification of Cell-Specific, Internalizing RNA Aptamers with Bioinformatics Analyses of a Cell-Based Aptamer Selection , 2012, PloS one.

[33]  J. Otlewski,et al.  Tumor-specific hyperthermia with aptamer-tagged superparamagnetic nanoparticles , 2013, International journal of nanomedicine.

[34]  Matthias John,et al.  Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs , 2004, Nature.

[35]  Dorma C. Flemister,et al.  Selective Light-Triggered Release of DNA from Gold Nanorods Switches Blood Clotting On and Off , 2013, PloS one.

[36]  Yinan Zhong,et al.  Ligand-directed active tumor-targeting polymeric nanoparticles for cancer chemotherapy. , 2014, Biomacromolecules.

[37]  Tetsuro Tanaka,et al.  Tumor targeting based on the effect of enhanced permeability and retention (EPR) and the mechanism of receptor-mediated endocytosis (RME). , 2004, International journal of pharmaceutics.

[38]  Ronghua Yang,et al.  Regulation of singlet oxygen generation using single-walled carbon nanotubes. , 2008, Journal of the American Chemical Society.

[39]  S. Ryu,et al.  Aptamer-modified magnetic nanoprobe for molecular MR imaging of VEGFR2 on angiogenic vasculature , 2013, Nanoscale Research Letters.

[40]  M. Avci-Adali,et al.  Pitfalls of cell-systematic evolution of ligands by exponential enrichment (SELEX): existing dead cells during in vitro selection anticipate the enrichment of specific aptamers. , 2010, Oligonucleotides.

[41]  Xiaoyan Zhu,et al.  Investigation on novel chitosan nanoparticle-aptamer complexes targeting TGF-β receptor II. , 2013, International journal of pharmaceutics.

[42]  P. Tinnefeld,et al.  One-pot synthesized aptamer-functionalized CdTe:Zn2+ quantum dots for tumor-targeted fluorescence imaging in vitro and in vivo. , 2013, Analytical chemistry.

[43]  Tao Chen,et al.  Self-assembled hybrid nanoparticles for targeted co-delivery of two drugs into cancer cells. , 2014, Chemical communications.

[44]  Li Tang,et al.  Aptamer-functionalized, ultra-small, monodisperse silica nanoconjugates for targeted dual-modal imaging of lymph nodes with metastatic tumors. , 2012, Angewandte Chemie.

[45]  Anthony D. Keefe,et al.  Direct in vitro selection of a 2'-O-methyl aptamer to VEGF. , 2005, Chemistry & biology.

[46]  W. Tan,et al.  Aptamers recognizing glycosylated hemagglutinin expressed on the surface of vaccinia virus-infected cells. , 2010, Analytical chemistry.

[47]  B. Sullenger,et al.  In vivo selection of tumor-targeting RNA motifs , 2009, Nature chemical biology.

[48]  R. Duncan Polymer therapeutics as nanomedicines: new perspectives. , 2011, Current opinion in biotechnology.

[49]  John C. Burnett,et al.  Current Progress of RNA Aptamer-Based Therapeutics , 2012, Front. Gene..

[50]  Jinhui Wu,et al.  Nucleolin targeting AS1411 modified protein nanoparticle for antitumor drugs delivery. , 2013, Molecular pharmaceutics.

[51]  Volker A Erdmann,et al.  Application of locked nucleic acids to improve aptamer in vivo stability and targeting function. , 2004, Nucleic acids research.

[52]  Xin Li,et al.  Immunofluorescence assay and flow-cytometry selection of bead-bound aptamers. , 2003, Nucleic acids research.

[53]  Tracy R. Keeney,et al.  From SOMAmer-Based Biomarker Discovery to Diagnostic and Clinical Applications: A SOMAmer-Based, Streamlined Multiplex Proteomic Assay , 2011, PloS one.

[54]  Mark E. Davis,et al.  Nanoparticle therapeutics: an emerging treatment modality for cancer , 2008, Nature Reviews Drug Discovery.

[55]  Y. Zu,et al.  Oligonucleotide Aptamers: New Tools for Targeted Cancer Therapy , 2014, Molecular therapy. Nucleic acids.

[56]  Jianjun Cheng,et al.  Polymeric Nanomedicines Based on Poly(lactide) and Poly(lactide-co-glycolide). , 2012, Current opinion in solid state & materials science.

[57]  Omid C Farokhzad,et al.  Aptamer-functionalized nanoparticles for medical applications: challenges and opportunities. , 2012, ACS nano.

[58]  B. Sullenger,et al.  Gene therapy progress and prospects: RNA aptamers , 2007, Gene Therapy.

[59]  William H. Thiel,et al.  Identification of RNA aptamers that internalize into HPV-16 E6/E7 transformed tonsillar epithelial cells. , 2013, Virology.

[60]  Jie Li,et al.  Identification of an aptamer targeting hnRNP A1 by tissue slide‐based SELEX , 2009, The Journal of pathology.

[61]  Peixuan Guo,et al.  Specific delivery of therapeutic RNAs to cancer cells via the dimerization mechanism of phi29 motor pRNA. , 2005, Human gene therapy.

[62]  Peixuan Guo,et al.  Thermodynamically Stable RNA three-way junctions as platform for constructing multi-functional nanoparticles for delivery of therapeutics , 2011, Nature Nanotechnology.

[63]  Paloma H. Giangrande,et al.  Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers , 2012, Nucleic acids research.

[64]  Silvia Catuogno,et al.  Inhibition of receptor signaling and of glioblastoma-derived tumor growth by a novel PDGFRβ aptamer. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[65]  Kemin Wang,et al.  Au@Ag/Au nanoparticles assembled with activatable aptamer probes as smart "nano-doctors" for image-guided cancer thermotherapy. , 2014, Nanoscale.

[66]  David E. Smith,et al.  Impact of intestinal PepT1 on the kinetics and dynamics of N-formyl-methionyl-leucyl-phenylalanine, a bacterially-produced chemotactic peptide. , 2013, Molecular pharmaceutics.

[67]  K. Neoh,et al.  PEGylated anti-MUC1 aptamer-doxorubicin complex for targeted drug delivery to MCF7 breast cancer cells. , 2011, Macromolecular bioscience.

[68]  An RNA Alternative to Human Transferrin: A New Tool for Targeting Human Cells , 2012, Molecular therapy. Nucleic acids.

[69]  E. Ng,et al.  Anti‐VEGF Aptamer (Pegaptanib) Therapy for Ocular Vascular Diseases , 2006, Annals of the New York Academy of Sciences.

[70]  Tracy R. Keeney,et al.  Aptamer-based multiplexed proteomic technology for biomarker discovery , 2010, Nature Precedings.

[71]  Prahlad T. Ram,et al.  2′-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity , 2014, Nature Communications.

[72]  Anthony D. Keefe,et al.  SELEX with modified nucleotides. , 2008, Current opinion in chemical biology.

[73]  D. Shangguan,et al.  Aptamers evolved from live cells as effective molecular probes for cancer study , 2006, Proceedings of the National Academy of Sciences.

[74]  M. Famulok,et al.  Prion‐Protein‐Specific Aptamer Reduces PrPSc Formation , 2002, Chembiochem : a European journal of chemical biology.

[75]  Robert Langer,et al.  Superparamagnetic Iron Oxide Nanoparticle-Aptamer Bioconjugates for Combined Prostate Cancer Imaging and Therapy , 2011 .

[76]  L. Gold,et al.  Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. , 1990, Science.

[77]  V. C. Özalp,et al.  Targeting cancer cells with controlled release nanocapsules based on a single aptamer. , 2013, Chemical communications.

[78]  S. Klußmann,et al.  Spiegelmers: Biostable Aptamers , 2003, Chembiochem : a European journal of chemical biology.

[79]  J. Richie,et al.  Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[80]  J. Cheong,et al.  Maleimidyl magnetic nanoplatform for facile molecular MRI , 2014, Nanotechnology.

[81]  B. Sullenger,et al.  Aptamers: an emerging class of therapeutics. , 2005, Annual review of medicine.

[82]  M. Hutmacher,et al.  Population Pharmacokinetics of Pegaptanib in Patients With Neovascular, Age‐Related Macular Degeneration , 2012, Journal of clinical pharmacology.

[83]  Weihong Tan,et al.  Generating aptamers for recognition of virus-infected cells. , 2009, Clinical chemistry.

[84]  C. Thaxton,et al.  Update on current and potential nanoparticle cancer therapies , 2013, Current opinion in oncology.

[85]  John T McDevitt,et al.  Aptamer-based sensor arrays for the detection and quantitation of proteins. , 2004, Analytical chemistry.

[86]  Kemin Wang,et al.  ATP-responsive controlled release system using aptamer-functionalized mesoporous silica nanoparticles. , 2012, Langmuir : the ACS journal of surfaces and colloids.

[87]  J. Szostak,et al.  In vitro selection of RNA molecules that bind specific ligands , 1990, Nature.

[88]  Weihong Tan,et al.  In vitro Selection of DNA Aptamers to Glioblastoma Multiforme. , 2011, ACS chemical neuroscience.

[89]  Peixuan Guo,et al.  Ultrastable synergistic tetravalent RNA nanoparticles for targeting to cancers. , 2012, Nano today.

[90]  Zhi Zhu,et al.  Monoclonal surface display SELEX for simple, rapid, efficient, and cost-effective aptamer enrichment and identification. , 2014, Analytical chemistry.

[91]  Rebecca Richards-Kortum,et al.  Aptamer-Targeted Gold Nanoparticles As Molecular-Specific Contrast Agents for Reflectance Imaging , 2008, Bioconjugate chemistry.

[92]  Alfonso Latorre,et al.  DNA and aptamer stabilized gold nanoparticles for targeted delivery of anticancer therapeutics. , 2014, Nanoscale.

[93]  A D Ellington,et al.  Aptamers as therapeutic and diagnostic reagents: problems and prospects. , 1997, Current opinion in chemical biology.

[94]  Q. Ma,et al.  A novel aptamer functionalized CuInS2 quantum dots probe for daunorubicin sensing and near infrared imaging of prostate cancer cells. , 2014, Analytica chimica acta.

[95]  Dong Liang,et al.  Selective Uptake and Imaging of Aptamer- and Antibody-Conjugated Hollow Nanospheres Targeted to Epidermal Growth Factor Receptors Overexpressed in Head and Neck Cancer , 2014, ACS nano.

[96]  E. Ng,et al.  Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. , 2005, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.

[97]  Liyu Li,et al.  Nucleolin-targeting liposomes guided by aptamer AS1411 for the delivery of siRNA for the treatment of malignant melanomas. , 2014, Biomaterials.

[98]  D. Volk,et al.  X-aptamers: a bead-based selection method for random incorporation of druglike moieties onto next-generation aptamers for enhanced binding. , 2012, Biochemistry.

[99]  Mohammad Ramezani,et al.  Reversible targeting and controlled release delivery of daunorubicin to cancer cells by aptamer-wrapped carbon nanotubes. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[100]  Omid C Farokhzad,et al.  Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. , 2012, Chemical Society reviews.

[101]  A. Adamis,et al.  Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration. , 2007, Ophthalmology.

[102]  Jian Wang,et al.  Aptamer-conjugated nanorods for targeted photothermal therapy of prostate cancer stem cells. , 2013, Chemistry, an Asian journal.

[103]  N. Zhao,et al.  A nanocomplex that is both tumor cell-selective and cancer gene-specific for anaplastic large cell lymphoma , 2011, Journal of nanobiotechnology.

[104]  Amy C Yan,et al.  Cell internalization SELEX: in vitro selection for molecules that internalize into cells. , 2014, Methods in molecular biology.

[105]  N. Zhao,et al.  Immunotherapy of CD30-expressing lymphoma using a highly stable ssDNA aptamer. , 2013, Biomaterials.